Volume 2, Issue 1

Chair’s Welcome

Practice Edge


CPO Corner

E-Discovery and Digital Evidence Case Digest

Meet the Rainmakers

Nanotechnology for Promise or Peril?

• SciStatus Update

• Shifting Strategies for Protecting Music Online



• ABA Annual Meeting SciTech Events & CLE Programs

• Call to Action: CTC3 Articles Sought!

• Connect with SciTech's Linked In Group

• Join SciTech's Facebook Fan Page

• Order Forensic Science for the 21st Century

Outreach in Abu Dhabi

• Register for Digital Law Conference

• Student Testimonial



2009 ABA Annual Meeting
Swissotel Chicago
July 29 - August 2, 2009

Seven Secrets Every Lawyer Must Know to Thrive, Even in a Recession
August 25, 2009 - August 25, 2009
Format: Teleconference

Domestic Protection of Cleantech IP
September 15, 2009 - September 15, 2009
Format: Teleconference

ABA Connection on Food Safety
September 15, 2009
Sponsored by ABA Journal and ABE Center on CLE

Arming for the Cleantech Revolution: The United States Prepares Landmark Federal and State Legislation to Save the Climate and the Economy
September 29, 2009

Digital Law Conference
September 23-24, 2009
San Jose, CA


 The advancement of technology in the past decade has catapulted the prominence of electronic evidenc... Read More

 This book provides you with a legal and practical approach to the new world of digital information. It has been described as a must have  for litigation lawyers, corporate counsel and records managers who want to understand how to appropriately handle the digital information of an enterprise. Read more.

The SciTech Lawyer

 The Section’s quarterly magazine features practical and timely articles on a diverse range of science and technology law issues. This issue focuses on biosecurity.

Contact Us

The SciTech e-Merging News is published quarterly as a Section member benefit. Click here to join the Section. The material published reflects the views of the authors and has not been approved by the Section of Science & Technology Law, the House of Delegates or the Board of Governors of the ABA. © 2009 American Bar Association. All rights reserved.

Practice Edge

bio blurb by eileen smith ewing

Faithful BioBlurb readers, thanks for waiting patiently during the changing of the guard (of our editors, that is). 

We've said good-bye, sadly, to our editor extraordinaire of the past two years, Lisa von Biela.  (Lisa is studying for the bar examination and preparing for the full-time practice of law.)   While we wait for our official 2009-10 Blurb leadership to take over, an interim editorial team from the Committee on Biotechnology will keep the BioBlurb coming your way. 

Please do keep sending your contributions to the Blurb to eileen.ewing@klgates.com.  Thanks to Hugh Wellons for providing a lot of this week's material! 

Research Breakthroughs :

"Novartis, Fate Race to Develop Stem Cell Drug for Transplants."  For thousands of blood cancer victims who need a bone marrow transplant or umbilical cord blood but can't find a match, the competition between Fate Therapeutics and Novartis to develop a stem cell therapy is good news regardless who gets there first, reports Bloomberg.com (July 9, 2009). 

"Portable DNA Purifier for Poor Countries."  A new handheld device can isolate DNA from human fluid without the use of electrical power, a breakthrough likely to prove a boon to impoverished or rural communities, according to the MIT Technology Review (July 10, 2009). 


"Easter Island Wonder Drug 'Adds Decade to Life.'" Researchers at the Jackson Laboratory believe that rapamycin, a bacterial product found in soil samples in the South Pacific, could extend the human lifespan, by inhibiting a protein that plays a key role in cell growth, reports The Sun (July 9, 2009).


"Australian Scientists Kill Cancer Cells with 'Trojan Horse.'"  The therapy uses a bacterially-derived nano cell as a "Trojan horse" to penetrate and disarm a cancer cell before a second nano cell kills it with chemotherapy drugs, according to Yahoo! News (June 28, 2009). 

"Protein May Open Door to New Drugs."  Brown University scientists suggest that a protein found on brain cells, known to contribute to nicotine addiction, may also be the key to developing drugs for a wide range of diseases and medical conditions, including obesity, schizophrenia, and Alzheimer’s disease, according to The Boston Globe (June 29, 2009).


"Hundreds of Genes May Be Linked to ADHD."  Findings published in Molecular Psychiatry may offer a partial explanation of why there are so many variations in how ADHD patients present clinically, according to Yahoo! News (June 25, 2009). 


Follow-On Biologics:

"Study Endorses Longer Market Exclusivity for Drugmakers."  The National Venture Capital Association released study results supporting a longer period of market exclusivity for biologic drugmakers before follow-ons are allowed on the market, according to a Wall Street Journal blog (July 13, 2009).  

"Biotech Drug Copies Could Be Held Up 13 Years Under Senate Plan."  A bill filed by Sen. Edward Kennedy (D-Mass.) would give over 13 years' market exclusivity to existing biologics, but the bill is subject to amendment by other senators, according to Bloomberg.com (July 8, 2009).

"White House: 7 Years Enough to Shield Biotech Drugs."  A seven-year period of market exclusivity would strike the right balance between innovation and competition, according to White House officials quoted by Reuters (June 25, 2009).


Drug Deals:

"Johnson & Johnson Completes Cougar Biotech Deal."  J&J paid $893.7 million in a tender offer for Cougar, a biotech company developing a potential treatment for prostate cancer, according to The Boston Globe (July 10, 2009).

"Merck Acquires Right to Anticoagulant."  Merck licensed worldwide co-development rights to Portola's anticoagulant drug candidate, betrixaban, as a potential replacement for warfarin, according to The New York Times (July 9, 2009).


Intellectual Property Issues:

"International Development Minister Urges Firms to Pool HIV Patents."  Predicting a worldwide HIV treatment crisis by 2030, Mike Foster, the UK's International Development Minister, urges pharmaceutical companies to eschew patent protection and contribute their breakthroughs in the HIV area to a patent pool to be set up by the international drug-purchasing facility Unitaid, reports The Guardian (July 12, 2009).



"House Approves $2.99 Billion FDA Budget."  The House of Representatives voted 266 to 160 to approve the largest budgetary increase in the FDA's history, according to the Wall Street Journal (July 9, 2009). 


SBIR Grants for Biotech Startups:

"Funding Bill for Start-Ups Criticized."  Venture capitalists and companies are at odds over who should get grants under a new SBIR scheme, according to the Washington Post (July 8, 2009).


Health Care Reform:

"Health Care Deadline Unlikely to Be Met ."  President Obama's August deadline for health care reforms seems unlikely to be met, according to Politico (July 9, 2009).


Key Political Appointments:

"Alabama Physician Chosen as Surgeon General."  President Obama has chosen Dr. Regina Benjamin, a family physician whose clinic served Hurricane Katrina victims and who received a MacArthur Foundation "genius" grant last year, as the next U.S. Surgeon General, says The New York Times (July 13, 2009).


And, As Always, Weird News:

"Study: Ugly Men More Fertile, Produce More Sperm During Sex."  A study suggests that women seeking to get pregnant have a better chance with an ugly partner, reports Fox News (July 10, 2009). 


Eileen Smith Ewing
K&L Gates LLP
ABA Section of Science & Technology Law
Biotechnology Law Committee Chair


Bio Blurb is a member benefit of the Biotechnology Law Committee. Join the Committee for free to receive your regular issue.